HGPS is not usually passed down in families. The gene change is almost always a chance occurrence that is extremely rare. Children with other types of “progeroid” syndromes which are not HGPS may have diseases that are passed down in families. However, HGPS is a “sporadic autosomal dominant” mutation – sporadic because it is a new change in that family, and dominant because only one copy of the gene needs to be changed in order to have the syndrome. For parents who have never had a child with Progeria, the chances of having a child with Progeria are 1 in 4 – 8 million.
No treatment has demonstrated successful. Most treatment focuses on lessening intricacies, (for example, cardiovascular infection) with corocoronary artery bypass surgery or low-doseaspirin. Children might likewise profit by a high-vitality diet. Development hormone treatment has been endeavored. The utilization of Morpholinos has additionally been endeavored so as to lessen progerin generation. Farnesyltransferase inhibitors (FTIs) are medications that restrain the movement of a chemical required with a specific end goal to make a connection between progerin proteins and farnesyl bunches. Pravastatin, exchanged as Pravachol or Selektine, is incorporated into the group of statins. And additionally zoledronate (otherwise called Zometa and Reclast, which is a bisphosphonate), its utility in HGPS is the counteractive action of farnesyl gathering arrangement, which progerin needs to provoke the disease.